how the concept of fitness in cll has changed with the introduction of novel targeted agents
Published 1 year ago • 186 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
1:01
cll resistance mechanisms in the era of novel agents
-
1:28
challenges with defining fitness in cll & important comorbidities to consider when selecting therapy
-
5:03
understanding patient perspectives in cll treatment
-
0:45
key trials in cll and designing a concept for treatment
-
3:29
how the management of cll is evolving
-
1:51
understanding and overcoming resistance mechanisms to novel agents used in cll
-
0:53
the future of cll treatment
-
1:28
the future of cll treatment
-
1:02:10
what is cll? - diagnosis and treatment
-
4:02
living with chronic lymphocytic leukaemia (cll)
-
7:42
cll / sll leukemia basics
-
1:35
the future directions of cll research: mechanisms of pathogenesis and novel biomarkers
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
3:14
understanding cll pathogenesis by assessing clonotypes
-
1:20
the importance of cardio-oncology in cll
-
1:19
cll treatment: a look into the future
-
3:03
the evolution of treatment patterns and prognostic biomarkers in latin american cll patients
-
1:10
the pathways of cll pathogenesis and cll’s relationship with mbl
-
1:20
mechanisms of resistance in cll and how they can be predicted
-
1:25
the management of cll in italy
-
3:46
the characteristics and mode of action of ibrutinib for cll
-
1:12
insights into the optimal management of cll: the importance of patient characteristics